To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment

NAUnknownINTERVENTIONAL
Enrollment

888

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

October 30, 2021

Study Completion Date

July 31, 2022

Conditions
Sterility
Interventions
PROCEDURE

GnRH-ant protocol

Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.

PROCEDURE

GnRH-a long protocol

The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.

Trial Locations (4)

100000

RECRUITING

Peking University Third Hospital, Beijing

210000

RECRUITING

Jiangsu Provincial Hospital, Nanjing

300000

RECRUITING

The second hospital of Hebei Medical University, Baoding

450000

RECRUITING

The third hospital of Zhengzhoui Medical University, Zhengzhou

All Listed Sponsors
collaborator

Merck Serono GmbH, Germany

INDUSTRY

collaborator

Fountain Medical Development Co., Ltd.

INDUSTRY

collaborator

Guangzhou KingMed Center for Clinical Lab.Co., Ltd

UNKNOWN

lead

Peking University Third Hospital

OTHER

NCT04026282 - To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment | Biotech Hunter | Biotech Hunter